| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Therapeutic and Economic Comparison of the Top Innovative New Drugs of the 1970s and 1980s
|
Althuis, Thomas H.
|
|
1992
|
26 |
2 |
p. 279-287
|
artikel
|
| 2 |
Carcinogenicity Testing of Therapeutics
|
Weissinger, Judi
|
|
1992
|
26 |
2 |
p. 133-140
|
artikel
|
| 3 |
Conduct of Investigator Site Audits in Europe by Clinical Quality Assurance Personnel
|
Neal, Harold
|
|
1992
|
26 |
2 |
p. 211-218
|
artikel
|
| 4 |
Editorial: Software Survey Section
|
|
|
1992
|
26 |
2 |
p. i-iii
|
artikel
|
| 5 |
Format and Content of a Statistical Data Item
|
Berman, Rayanne S.
|
|
1992
|
26 |
2 |
p. 187-190
|
artikel
|
| 6 |
North Dakota Pharmacists' Need for Drug Information: 1990 VS 1980
|
Koo, Ji M.
|
|
1992
|
26 |
2 |
p. 237-242
|
artikel
|
| 7 |
Opening Remarks — Clinical Trial Supplies
|
Ameline, Claude
|
|
1992
|
26 |
2 |
p. 267-269
|
artikel
|
| 8 |
Patient Product Information (PPI) – Elements for a Rational Approach
|
Blattmann, Paul
|
|
1992
|
26 |
2 |
p. 271-278
|
artikel
|
| 9 |
Pitfalls in the Drug Approval Process: Dose-Effect, Experimental Design, and Risk-Benefit Issues
|
Miller, Loren L.
|
|
1992
|
26 |
2 |
p. 251-260
|
artikel
|
| 10 |
Postmarketing Studies: Methods for Implementation and Potential Use of Data
|
Toscani, Michael R.
|
|
1992
|
26 |
2 |
p. 261-265
|
artikel
|
| 11 |
Qualifications of Investigators for Clinical Investigations Conducted under an Ind: A Discussion Paper
|
Cocchetto, David M.
|
|
1992
|
26 |
2 |
p. 167-173
|
artikel
|
| 12 |
Removing the Mystique Surrounding Optical Disk Technology
|
Corak, Robert
|
|
1992
|
26 |
2 |
p. 163-165
|
artikel
|
| 13 |
Rx to OTC Conversions: The Role of Epidemiology
|
Friedman, Rhonda B.
|
|
1992
|
26 |
2 |
p. 149-154
|
artikel
|
| 14 |
The Contribution of Epidemiology to Pharmacoeconomic Research
|
Chrischilles, Elizabeth A.
|
|
1992
|
26 |
2 |
p. 219-229
|
artikel
|
| 15 |
The Food and Drug Administration Perspective on the Importance of Dialogue with Industry
|
Meyer, Gerald F.
|
|
1992
|
26 |
2 |
p. 159-161
|
artikel
|
| 16 |
The Impact of Regulatory Issues in Contract Negotiations
|
Yingling, Gary L.
|
|
1992
|
26 |
2 |
p. 155-158
|
artikel
|
| 17 |
The Measurement of Efficiency in Clinical Research and Development
|
Moran, Mark
|
|
1992
|
26 |
2 |
p. 201-209
|
artikel
|
| 18 |
The Pfizer International Medical Management System (PIMMS): Tracking Worldwide Registration and Commercialized Products
|
Petrick, Robert J.
|
|
1992
|
26 |
2 |
p. 175-186
|
artikel
|
| 19 |
The Relationship of Changes in Headcount to Go/No Go Decisions
|
Moran, Mark
|
|
1992
|
26 |
2 |
p. 301-309
|
artikel
|
| 20 |
The Systems Approach as a Paradigm for Pharmaceutical Research: A Proposal
|
Lacy, Mark E.
|
|
1992
|
26 |
2 |
p. 243-249
|
artikel
|
| 21 |
Training and Development of Clinical Research Personnel through the Glaxo Professional Development Program
|
White, Kevin Darryl
|
|
1992
|
26 |
2 |
p. 289-299
|
artikel
|
| 22 |
Unlabeled Uses of Approved Drugs
|
Nightingale, Stuart L.
|
|
1992
|
26 |
2 |
p. 141-147
|
artikel
|
| 23 |
Value of Historical Controls in the Interpretation of Rodent Tumor Data
|
Haseman, J. K.
|
|
1992
|
26 |
2 |
p. 191-200
|
artikel
|
| 24 |
When is a Drug Not a Drug? the L-Tryptophan Tragedy: Lessons to Be Learned
|
Benjamin, David M.
|
|
1992
|
26 |
2 |
p. 231-236
|
artikel
|
Tijdschrift beschrijving